|Bid||0.00 x 0|
|Ask||129.89 x 100|
|Day's Range||95.71 - 98.68|
|52 Week Range||49.19 - 153.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 3, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||155.59|
Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced new results from the Phase 1 and Phase 1/2 open-label extension studies of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyrias .
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $105 million.
Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.
On Monday, April 2, 2018, CASI Pharmaceuticals (CASI) stock opened at $4.20. It grew ~68% over the week to close at $7.01 on April 6. Its 52-week low was $0.91 on June 20, 2017.
Who's the world's best hedge fund manager? David Tepper? Stevie Cohen? Try Joe Edelman, a wannabe psychologist with a bead on biotech who has quietly built the best track record of the past two decades.
Here's a few must-watch biotech catalysts this week . Conferences Panamerican League of Associations for Rheumatology Congress – April 7-11 at Hotel Hilton, Buenos Aires, Argentina. The International Liver ...
On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.
Zosano Pharma Corporation (NASDAQ:ZSAN) was a real end of the week mover in the biotechnology sector last week, with the company sliding close to 45% on the news that it is set to conduct an underwritten public offering. The public offering will see Zosano issue 10 million shares at an average price of five dollars […] The post Here’s What Just Happened With Zosano Pharma Corporation And Pfizer Inc appeared first on Market Exclusive.
Alnylam and Ionis stocks fell Monday after Dow Jones component Pfizer announced strong results for a competing rare-disease drug.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) continued to decline after Pfizer Inc. (NYSE: PFE ) reported its transthyretin stabilizer Vyndaqel met primary Phase 3 endpoints Thursday. However, B Riley ...
These headlines first appeared on Benzinga Pro . Stifel on Walmart Inc (NYSE: WMT ), Humana Inc (NYSE: HUM ) WSJ report: Expansion of an existing prescription drug plan partnership 'is most likely,' would ...
Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.
Alnylam and Ionis toppled Thursday after Dow Jones component Pfizer unveiled strong late-stage results for a competing rare-disease drug.
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that Alnylam scientists and collaborators will present new results from the Phase 1 and Phase 1/2 open-label extension studies of givosiran, its investigational RNA interference therapeutic, in patients with acute hepatic porphyrias at the European Association for the Study of the Liver 53rd Annual International ...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that the Company presented new results from the APOLLO Phase 3 study of patisiran, an investigational, RNAi therapeutic for the treatment of hereditary ATTR amyloidosis at the 16th International Symposium on Amyloidosis , being held March 26-29, 2018 in Kumamoto, Japan.